Trial Profile
A Randomized, Two-arm, Observer-blind, Parallel-group, Activecontrolled, Multi-center Clinical Study to Evaluate the Immunogenicity and Safety of Influvac Tetra compared to VaxiFlu-4 in Healthy Adult and Elderly Subjects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Jul 2019
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Abbott Healthcare
- 05 Dec 2018 Status changed from active, no longer recruiting to completed.
- 25 Jun 2018 New trial record